ALSO NOTED: YM cleared for Phase II; pine needle approach studied for ulcers; Applera in buyback plan; and much more...

> YM BioSciences has received FDA approval initiate a Phase II trial investigating nimotuzumab in pediatric patients. Release

> A prominent Russian scientist has been testing an experimental therapy made from green pine needles for helicobacter pylori bacterium (H.pylori), the root cause of stomach ulcers. FierceBioResearcher

> Applera, which owns the biotech company Applied Biosystems, has accelerated the repurchase of $600 million worth of its Applied Biosystems' shares. Report

> Pharmexa says it has prevailed against Geron in a patent dispute. Release

And Finally... Tiny fat bubbles can be used to deliver powerful chemotherapy drugs to tumor sites. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.